CASBF (CanSino Biologics) 10-Year Sortino Ratio: N/A (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASBF CanSino Biologics Inc CASBF
65 GF Score
Price $4.60
GF Value $9.24
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is CanSino Biologics 10-Year Sortino Ratio?

The 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. As of today (2026-09-10), CanSino Biologics's 10-Year Sortino Ratio is Not available.


CanSino Biologics  (OTCPK:CASBF) 10-Year Sortino Ratio Explanation

The 10-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past ten year. It is calculated as the annualized result of the average ten-year monthly excess returns divided by the standard deviation of negative returns in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


CanSino Biologics 10-Year Sortino Ratio Related Terms


CASBF vs ZTS: 10-Year Sortino Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's 10-Year Sortino Ratio, along with its competitors' market caps and 10-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics 10-Year Sortino Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's 10-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's 10-Year Sortino Ratio falls into.


CASBF
65GF Score
CanSino Biologics Inc CASBF
10-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CanSino Biologics 10-Year Sortino Ratio Calculation

The 10-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last ten year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 10-Year Sortino Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past ten year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Is CanSino Biologics (CASBF) Overvalued in 2026?

Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued. The current stock price of $4.60 is trading 50.2% below its estimated GF Value™ of $9.24. GuruFocus considers CanSino Biologics to be Significantly Undervalued.

Key valuation signals for CASBF:

  • 10-Year Sortino Ratio: N/A
  • GF Value™: $9.24 vs. price of $4.60 (50.2% below fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CanSino Biologics Business Description

Address 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
65GF Score

Get the complete analysis for CASBF

10-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.60
Price
$9.24
GF Value